In addition, AF is responsible for 15% to 36% of all strokes, and AF-related strokes are associated with worse prognosis when compared to nonarrhythmic ones. 2-4 Even very short (of 5-to 6-minute duration), asymptomatic episodes of AF may significantly increase the probability of stroke and death. For these reasons, an appropriately assessed risk of stroke and preventive measures against thromboembolic complications are of paramount importance in AF patients.
5,6
To the best of our knowledge, there are limited data thus far comparing stroke prevention strategies in AF patients in Poland and other European countries. Little is also known on the treatment strategies in high-and low-risk AF patients in Poland and how these strategies comply with the current guidelines of the European Society of Cardiology (ESC). 7, 8 The lack of knowledge on this topic may result in inappropriate stroke prevention or nonadequate treatment in Poland and, consequently, higher ischemic or bleeding risks among AF patients. Recently published data suggest that the proportion of patients with CHA 2 DS 2 -VASc scores of 2 to 8 treated with oral anticoagulants (OACs) may be as low as 78%. Paradoxically, as many as half of the AF population with a CHA 2 DS 2 -VASc score of 0 are treated with OACs. 9 The aim of this analysis was to assess treatment strategies and their association with baseline AF patients' characteristics in Poland compared with other members of the European Union (EU), based on data derived from a large, contemporary European registry. Specifically, we aimed to investigate the adherence to current ESC recommendations regarding treatment of both highand low-risk AF groups among Polish physicians involved in AF management.
PAtIents And methods
The EURObservational Research Programme is a system of registries that was initiated by the ESC in 2009 to better understand medical practice among physicians involved in cardiovascular care, based on a broad scope of observational data collected throughout European countries. The methodology of the EURObservational Research ProgrammeAtrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry) has been published elsewhere. 9, 10 In brief, the aim of the registry was to assess complications related to AF across Europe in order to confirm whether diagnostic and treatment methods remain concordant with the current ESC recommendations, and to verify whether they affect outcomes in AF patients.
The registry population consisted of consecutive inpatients and outpatients presenting to cardiologists with AF as the main diagnosis or as a comorbid condition. To be included in the registry, patients had to have AF within the last year recorded on an electrocardiogram, but they did not need to be in arrhythmia at the time of enrollment. The presentation of a patient or a planned approach (initiation of pharmacotherapy, value of less than 0.05 was considered statistically significant. All analyses were performed using the SAS statistical software version 9.4 (SAS Institute, Inc., Cary, North Carolina, United States).
results From among 3119 patients enrolled in 67 European investigator sites, 419 patients (13.4%) were included in 15 Polish centers. The reference profile of the enrolling sites was distributed differently in Poland compared with other participating countries. A greater proportion of Polish patients was enrolled in specialized centers than in other EU countries (75.5% vs 63.3% of patients; P <0.0001). More patients in Poland than in other EU countries were included in cardiology wards (75.9% vs 60.6%), whereas fewer patients were enrolled in outpatient clinics (22.2% vs 25.2%) and in private cardiology practices (0.2% vs 5.8%; P <0.0001).
baseline characteristics and arrhythmia type Patients enrolled in Poland differed with respect to several baseline characteristics compared with AF patients included in other participating countries (tAbles 1 and 2). Polish patients were younger, with borderline larger proportion of women, had greater prevalence of coronary artery disease (mainly in a form of stable angina), more often had a history of diabetes and arterial hypertension, as well as previous catheter ablation and pacemaker implantation. They were less prone to have chronic obstructive pulmonary disease or peripheral vascular disease and less often presented with hypertensive or hypertrophic cardiomyopathy. Patients enrolled in Poland had higher body mass index and lower systolic blood pressure. The mean CHADS 2 and CHA 2 DS 2 -VASc scores were distributed similarly between Polish patients and those from other countries (1.93 ±1.24 vs 1.92 ±1.28 and 3.21 ±1.78 vs 3.25 ±1.80, respectively), whereas HAS-BLED scores were lower in Polish patients than in those enrolled in other countries (1.22 ±1.03 vs 1.39 ±1.06; P = 0.003). Polish participants had lower left ventricular ejection fraction (LVEF), but less often had left ventricular hypertrophy detected on echocardiography. They had similar heart rates during sinus rhythm, but slower ventricular rates during AF than patients enrolled in other European countries (median heart rate of 90 and 92 bpm, respectively). Compared with patients from other EU countries, Polish patients presented less often with first-detected AF, but more often with paroxysmal AF (tAble 3).
management strategy and interventions performed
Patients enrolled in Poland were more often subjected to rhythm control only (20.8% vs 11.9%), whereas less often observation was the only intervention (1.0% vs 4.6%), compared with patients in other participating countries (tAble 3) . Among Polish inpatients (n = 323), pharmacological cardioversion was performed less often than in subjects from other EU countries (21.2% intended cardioversion or ablation) did not influence the inclusion. All patients provided written informed consent to participate in the registry. Twelve countries were initially invited to take part in the pilot phase, and finally 9 countries formally participated in the project. A minimum of 20 patients per center were to be enrolled, with the aim to enroll 3000 subjects. Finally, 3119 consecutive patients were included in 67 centers from 9 countries. Participating investigator sites presented a mixture of tertiary, secondary, and general hospitals but also included outpatient clinics with a broad range of diagnostic and therapeutic capabilities (with and without interventional cardiology units, electrophysiology, or on-site cardiac surgery). The registry schedule assumed 1 baseline visit and 1 visit per year over a 3-year period, but only data collected at baseline, during hospitalization (or outpatient visit), and at discharge were taken into account in this analysis.
statistical analysis A univariate analysis was applied both to continuous and categorical variables. Continuous variables were reported as mean ± standard deviation or as median and interquartile range. Categorical variables were reported as percentages. Between-group comparisons were made using the Kruskal-Wallis test for continuous variables and the χ 2 test or Fisher exact test for categorical variables, if any expected cell count was less than 5. A 2-sided P The Kruskal-Wallis test was used for quantitative data. The χ 2 or Fisher exact test (a) was used for binary variables.
For qualitative variables with more than 2 possibilities, the Monte Carlo estimates of the exact P values were used.
Abbreviations: CABG, coronary artery bypass grafting; CHF, congestive heart failure; IQR, interquartile range; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SD, standard deviation; TIA, transient ischemic attack ablation for AF therapy was more commonly performed in Polish patients during index hospitalization than in subjects from other EU countries (tAble 4) . This procedure was a more frequent approach in Polish patients younger than 69 years (21.2% vs 13.7%; P = 0.0112), in women (14.4% vs 7.1%; P = 0.0047), in those in NYHA class 2 or higher (8.8% vs 1.3%; P <0.0001), and in those with a CHA 2 DS 2 -VASc score of 3 or higher (6.9% vs 3.3%; P = 0.0154), but not in older patients, in men, and in those in NYHA class 1 (all P = nonsignifcant vs other EU countries). Catheter ablation for AF was used more commonly in Polish patients than in patients from other EU countries in cardiology wards (13 Polish women (18.8% vs 13%; P = 0.0342), patients aged 69 years or older (22.0% vs 13.2%; P = 0.0013) and those with LVEF of less than 55% (17.3% vs 9.2%; P = 0.0013) were discharged on DHP calcium channel blockers more often than patients in other participating countries. Non-DHP calcium channel blockers were used less frequently in Polish patients with LVEF of 55% or higher (3.2% vs 8.4%; P = 0.0127).
stroke, bleeding risk, and antithrombotic therapy
Any anticoagulation therapy (including antiplatelet agents and nonsteroidal anti-inflammatory drugs [NSAIDs]) was administered during hospital visit to 96.6% of Polish patients, similarly to other EU countries (P = 0.7940) (tAble 4). OACs, including vitamin K antagonists (VKAs), which is the most commonly prescribed OAC, were used in a smaller proportion of Polish inpatients than in other European countries (62.5% vs 73.8%; P <0.0001). Non-VKA OACs (NOACs), administered only to a small fraction of Polish patients, were also less frequently used in Poland than in other EU countries (3.5% vs 6.6%; P = 0.0391). On the other hand, the number of patients discharged from hospital on any antithrombotic treatment (including VKA, NOACs, antiplatelet drugs, and NSAIDs) reached 96.9% However, on discharge, the rates of antithrombotic therapy were comparable in Poland and the other countries participating in the EORP-AF registry, irrespectively of the CHA 2 DS 2 -VASc score (tAble 6) .
Considering bleeding risk, anticoagulants were given only to 53.7% of Polish inpatients who had a HAS-BLED score of 3 or higher, which was significantly less frequently than in other EU countries (70.4%; P = 0.0313). Among subjects with a lower risk of bleeding (HAS-BLED <3), in-hospital use of any anticoagulant was less frequent in Poland (tAble 6) . Conversely, proportions of patients discharged on anticoagulants were similar in Poland and subjects in other EU countries, irrespective of bleeding risk.
one-year outcomes During 1-year follow-up, the all-cause mortality rate was 4.2% in Polish patients and 6.6% in participants from other EU countries; cardiovascular mortality was 2.0% and 2.9%, respectively. Thrombotic events occurred in 6.0% of Polish patients and in 3.5% of patients enrolled in the remaining EU countries. These included stroke/transient ischemic attack (0.9% in Poland and 1.0% in other EU participants), acute coronary syndrome (1.2% and 0.8%), coronary intervention (4.8% and 2.0%), cardiac arrest (0.3% and 0.2%), peripheral embolism (0.0% and 0.2%), and pulmonary embolism (0.0% in Poland and other EU countries).
in Poland, and this proportion was similar to that in other European participating countries (tAble 5). This was also true for cardiology wards only (97.2% discharged on any OAC in Poland vs 96.0% in the remaining countries; P = 0.3305), and only non-cardiology centers (96.0% vs 93.3%; P = 0.2867) (Supplementary material online, Tables S5 and S6).
Proportions of patients with indications for anticoagulation (CHA 2 DS 2 -VASc ≥2 or planned cardioversion) receiving any OAC at discharge or after consultation were similar in Poland and in other EU countries (FIGure 1). Approximately one-third of patients were treated with antiplatelet agents during index hospitalization (P = 0.8599 vs other EU countries), and in 31.0% of patients these drugs were prescribed at discharge (P = 0.6559 vs other countries).
The use of OACs by CHA 2 DS 2 -VASc scores is shown in tAble 6. As many as 58.3% of Polish patients were still treated with VKAs and another 8.3% were treated with NOACs during hospitalization although their CHA 2 DS 2 -VASc score was 0; these proportions were similar in other European countries (59.1% and 9.7%, respectively; both P >0.9999). Polish inpatients with a CHA 2 DS 2 -VASc score of 2 or higher were receiving any anticoagulants (including VKAs, NOACs, antiplatelet agents, and NSAIDs) less frequently compared with the remaining EU countries. Subjects with higher stroke risk (CHA 2 DS 2 -VASc ≥3) were also anticoagulated less often in Poland (including use of ablation for AF in Poland than in other EU countries noted in this registry is in contrast with data published recently in the White Book of the European Heart Rhythm Association. Second, in the context of the profile of Polish enrolling centers, it is somewhat surprising that in-hospital use of OACs (both VKAs and NOACs) was less widespread in Poland compared with other EU countries. Polish participants had similar CHA 2 DS 2 -VASc scores and even lower HAS-BLED scores than participants from other countries. Although undertreatment with OACs can be partly explained by a greater proportion of Polish inpatients admitted for catheter ablation of AF, in a significant number of these patients, OACs were switched to another treatment, or even withdrawn completely before the procedure. The 2012 Heart Rhythm Society / EHRA / European Cardiac Arrhythmia Society Expert Consensus Statement on Ablation of Atrial Fibrillation suggested that catheter ablation of AF should be considered in patients who are therapeutically anticoagulated with warfarin.
13 Such an approach was also recommended by the 2012 focused update of the ESC guidelines for the management of AF.
8 Moreover, more data argue against "bridging" of antithrombotic drugs in patients undergoing catheter ablation. Indeed, data from a recent randomized trial comparing uninterrupted warfarin with low-molecular-weight heparin bridging in patients undergoing catheter ablation for AF showed that continuing warfarin during the periprocedural period reduced the occurrence of stroke and minor bleeding compared with bridging. Of note, VKA discontinuation was shown to be a strong predictor of periprocedural thromboembolism in this study. 14 Third, although the proportion of Polish patients discharged on OACs was high and similar to that in other EU countries, only 83% of patients with a CHA 2 DS 2 -VASc score of 2 or higher and even 76% of those with a CHA 2 DS 2 -VASc of 3 or higher were discharged from hospital on any anticoagulant. Although these numbers were not dissimilar from those in other EU countries, they indicate that as many as 1 in 5 to 1 in 4 patients leave the hospital without appropriate antithrombotic therapy. These data imply that adherence to the ESC guidelines still remains suboptimal and, paradoxically, becomes increasingly poor along with a progressively higher risk of dIscussIon The EORP-AF Pilot Registry provides an important and up-to-date view on during-visit and at-discharge treatment strategies of Polish patients with AF against the background of such strategies in other EU countries. Our country-specific registry data suggest that AF management strategies in Poland may differ from those applied in other EU countries.
First, compared with other EU countries, rhythm control strategy was more often adopted in Polish centers, whereas rate control was used less frequently. The least aggressive approach, namely, observation, was used in a significantly lower proportion of Polish patients, compared with other EU participating centers. Rhythm control strategy in Poland involved a more frequent use of AF ablation techniques in cardiology wards (especially in younger patients, in women, and in patients with NYHA class 2 or higher and with a CHA 2 DS 2 -VASc score of 3 or higher), and more often pharmacologic cardioversion in non-cardiology wards. Amiodarone was rarely prescribed at discharge in Poland, irrespectively of the type of center. On the contrary, β-blockers were prescribed significantly more often to Polish patients at discharge than to subjects discharged from hospitals in other EU countries. These data have to be interpreted with caution. Baseline characteristics of Polish patients were different from those enrolled in other EU countries (eg, higher prevalence of coronary artery disease may explain more common use of β-blockers).
11 The more widespread stroke. Undertreatment in high-risk groups may be partly explained by the presence of contraindications to the use of OACs, but even then it can be justified only in 13% to 18% of patients. 15, 16 Adherence to the ESC guidelines improved slightly over time (from 70% in the AFNET and Euro surveys to roughly 80% in the present registry), but still remains an important issue. [17] [18] [19] Furthermore, also in-hospital undertreatment with OACs seems to be progressively more pronounced among Polish inpatients with progressively higher bleeding risk. Current guidelines recommend only some caution and regular review in patients with high bleeding risk who are anticoagulated, in no way suggesting a HAS-BLED score of 3 or higher as a contraindication for the use of OACs. 7 Fourth, as many as two-thirds of Polish patients with very low risk of stroke (CHA 2 DS 2 --VASc = 0) were still treated with an OAC during their in-hospital visit, and a similar proportion was discharged home on an OAC. These numbers were similar in patients enrolled in other EU countries. As the current ESC guidelines recommend anticoagulation within periprocedural periods in patients undergoing cardioversion or AF ablation regardless of CHA 2 DS 2 -VASc scores (including 4-week postcardioversion and 8-week postablation anticoagulation), these numbers may at least partially be justified. 7, 13 But even taking into account proportions of Polish patients in whom cardioversion (21% pharmacological and 25% electrical, throughout all CHA 2 DS 2 VASc scores) or ablation was planned (13%), it still seems that a substantial proportion of patients is overtreated with OACs in Poland, despite having a very low stroke risk.
Finally, similar to other EU countries, antiplatelet therapy was still used in almost one-third of AF inpatients in Poland and a similar proportion was discharged from the hospital on antiplatelet agents. Antiplatelet drugs are not recommended by the ESC as effective antithrombotic agents to protect against stroke in AF patients. 7 Coronary artery disease may be responsible for such high proportions, and this factor was a significant determinant of antiplatelet drug use in AF subjects, also in the Eastern Europe, as previously shown. 20 This may be particularly true in Polish participants of the registry, almost 50% of whom (significantly more than in other EU countries, 35%) had diagnosis of coronary artery disease.
limitations Presented data come from a registry, and the inclusion of consecutive AF patients was one of its main goals. However, no screening-log was required by the registry protocol, thus selection bias or inclusion of nonconsecutive patients cannot be excluded. The present analysis focuses on baseline, in-hospital (or during outpatient visit), and at-discharge data only, and outcome data from the EORP-AF Pilot registry will become available in due course. The relatively small number of patients in some subgroups (for example the study, interpretation of data, revising the manuscript critically for important intellectual content, and final approval of the version to be submitted.
those with a CHA 2 DS 2 -VASc score of 0 or with a HAS-BLED score of 3 or higher), which led to significant inhomogeneity of the groups, may have potentially underpowered some significant associations. Differences in baseline patients' characteristics and diverse reference level of enrolling sites in Poland versus other countries made direct interregional comparisons impossible. Therefore, differences in treatment strategies between Poland and other EU countries should be perceived at best as hypotheses-generating.
In conclusion, a rhythm control-oriented strategy was more frequent in Polish centers, with more invasive approach preferred in cardiology wards. Similar to other EU countries, the compliance with the ESC guidelines regarding anticoagulation in AF patients could be improved in Poland, as there was undertreatment in a significant proportion of patients at high risk of stroke, and overtreatment in the low-risk group. Differences between the types of recruiting centers in Poland and other countries might have influenced the results.
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